Tetsuo Kobayashi - Olympus Executive Officer

OCPNF Stock  USD 16.00  0.00  0.00%   

Executive

Tetsuo Kobayashi is Executive Officer of Olympus
Phone81 3 3340 2111
Webhttps://www.olympus-global.com

Olympus Management Efficiency

The company has return on total asset (ROA) of 0.0815 % which means that it generated a profit of $0.0815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2329 %, meaning that it generated $0.2329 on every $100 dollars invested by stockholders. Olympus' management efficiency ratios could be used to measure how well Olympus manages its routine affairs as well as how well it operates its assets and liabilities.
Olympus has accumulated 333.85 B in total debt with debt to equity ratio (D/E) of 0.68, which is about average as compared to similar companies. Olympus has a current ratio of 1.95, which is within standard range for the sector. Debt can assist Olympus until it has trouble settling it off, either with new capital or with free cash flow. So, Olympus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Olympus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Olympus to invest in growth at high rates of return. When we think about Olympus' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

EXECUTIVE Age

Tomokazu YoshidaSysmex Corp
59
Marna BronfenMooreAngioDynamics
57
Hiroshi KandaSysmex Corp
66
Brian KoopmanUtah Medical Products
54
Scott CenteaAngioDynamics
45
Takashi OnoSysmex Corp
N/A
Saleem CheeksAngioDynamics
N/A
Laura PiccininiAngioDynamics
55
Juan SernaAngioDynamics
N/A
Mamoru KubotaSysmex Corp
N/A
Mark FoxUtah Medical Products
N/A
Mitsuhisa KanagawaSysmex Corp
N/A
Iwane MatsuiSysmex Corp
62
Marcena ClawsonUtah Medical Products
N/A
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. Olympus Corporation was incorporated in 1919 and is headquartered in Tokyo, Japan. Olympus Corp operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 31557 people. Olympus [OCPNF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Olympus Leadership Team

Elected by the shareholders, the Olympus' board of directors comprises two types of representatives: Olympus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Olympus. The board's role is to monitor Olympus' management team and ensure that shareholders' interests are well served. Olympus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Olympus' outside directors are responsible for providing unbiased perspectives on the board's policies.
Stefan Kaufmann, Executive Officer
Chikashi Takeda, Ex CFO
Andre Roggan, Ex CTO
Yasuo Takeuchi, Sr. Executive Managing Officer, Head of Corporate Management Office and Director
Nacho Abia, Executive Officer
Stephen Kneebone, Co Officer
Donna Miller, Head Counsel
Tetsuo Kobayashi, Executive Officer
Takaaki Sakurai, VP Relations
Shigeto Ohtsuki, Co Head

Olympus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Olympus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Olympus Pink Sheet

Olympus financial ratios help investors to determine whether Olympus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Olympus with respect to the benefits of owning Olympus security.